Low-dose Ara-C can cause complete remission of acute non-lymphocytic leukemia: differentiation induction?

Leukemia Research
J S YeM X Tao

Abstract

Fourteen patients with acute nonlymphocytic leukemia were treated with low-dose arabinosylcytosine (LDAC). Thirteen patients received subcutaneous injections at a dose of 10 mg/M2 every 12 h. One patient received 25 mg intramuscularly daily. All cases received one to three courses with each course lasting 10-60 days (median 19). Complete remission was achieved in 6 (or 43%) of the patients. Three patients had only cytoreduction and 5 patients did not respond. During the therapy severe thrombocytopenia occurred in all patients while prominent other cytopenias occurred in 10. Two-thirds of the patients achieving a remission had significant myelosuppression. There was one treatment-related death. During therapy 11 patients demonstrated a decrease in leukemia cells with an associated increase in differentiated granulocytes. This included 3 of the 4 complete remitters, and 3 of the 5 nonresponders. These results seem to suggest that the therapeutic effect of low-dose Ara-C may result from a combination of differentiation induction, cytotoxicity and unusual sensitivity of the leukemic cells to this agent.

References

Jul 1, 1979·British Journal of Haematology·M Baccarani, S Tura
Sep 1, 1979·British Journal of Clinical Pharmacology·A L HarrisD G Grahame-Smith
Aug 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·J Lotem, L Sachs
Apr 1, 1985·British Journal of Haematology·R T PerriM M Oken
Sep 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·J Lotem, L Sachs
Sep 1, 1984·British Journal of Haematology·H IshikuraH Uchino
Oct 1, 1984·British Journal of Haematology·S Whitehead, C G Geary
Dec 29, 1983·The New England Journal of Medicine·A Manoharan
Dec 29, 1983·The New England Journal of Medicine·G J MuftiA J Bell
May 15, 1980·International Journal of Cancer. Journal International Du Cancer·J Lotem, L Sachs
Jul 1, 1980·British Journal of Haematology·A L Harris, D G Grahame-Smith

❮ Previous
Next ❯

Citations

Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge Cortes, Hagop Kantarjian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.